We need to collaborate and test these innovations in controlled circumstances so that we can evaluate their effect and understand what needs to be iterated to continue to improve them, explained Harlan Krumholz, MD, SM, the Harold H. Hines Jr professor, Medicine and Epidemiology and Public Health, Yale School of Medicine, and director, Center for Outcomes Research and Evaluation, Yale-New Haven Hospital.
This page contains sponsored advertising
We need to collaborate and test these innovations in controlled circumstances so that we can evaluate their effect and understand what needs to be iterated to continue to improve them, explained Harlan Krumholz, MD, SM, the Harold H. Hines Jr professor, Medicine and Epidemiology and Public Health, Yale School of Medicine, and director, Center for Outcomes Research and Evaluation, Yale-New Haven Hospital.
Transcript
It seems like technology is improving at a faster pace than healthcare can keep up; how can we bridge that gap, so healthcare can better implement new technologies?
Corporations are the key for us to be able to adopt technology at a rapid pace and appropriately. The idea is that we have to all be holding hands collaborating and creating areas in places to test innovation and putting it in controlled circumstances so that we can evaluate their effect and understand what needs to be iterated and continue to improve them. If we don’t work together and create it within safe environments where we’re hyper measuring and understanding their impact, and then being able to scale out when appropriate, we’ll never really make progress because then we’ll just have different vendors and different companies trying to push different solutions and particularly on decision support, all of this needs to be evaluated thoroughly.
But, the problem is that we don’t really have places that are easy for that to be evaluated. We need to create test beds, places these can be tried, but tried in ways that are safe for patients, but still studied intensely so that we can learn from them. Otherwise, there’s a sense that healthcare is resistant to technology. I don’t think that is necessarily the case, I just think we don’t know exactly how to bring it forward. We know how to do that with drugs, we’re doing that with devices, and we could always use more data in those areas. But with regard to technology, we’re just feeling our way about, so when new technology comes out, how should we think about it? Do we think about it like drugs and devices, and if we do, how do we evaluate them quickly in appropriate places so that we can make progress?
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Key Indicators of Myasthenia Gravis Disease Progression Reduced With Efgartigimod
April 18th 2025Research presented at the recent annual meeting of the Academy of Managed Care Pharmacy highlights outcomes among patients who have anti-acetylcholine receptor antibody-positive myasthenia gravis that include reduced exacerbations and need for immunoglobulin.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Bias Reduction, Better Access Key to COVID-19 Equity Gains
April 14th 2025Interventions that target enhancing health care equity among communities disproportionately affected by the COVID-19 pandemic can be improved by including comprehensive needs assessments at the patient, provider, and health system levels.
Read More
Orca-T showed lower rates of graft-vs-host disease or infection compared with allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome (MDS) or acute leukemias in the Precision-T trial, Caspian Oliai, MD, MS, UCLA Bone Marrow Transplantation Stem Cell Processing Center, said.
Read More